Compare JBI & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBI | KOD |
|---|---|---|
| Founded | 2002 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 821.8M | 795.5M |
| IPO Year | N/A | 2018 |
| Metric | JBI | KOD |
|---|---|---|
| Price | $6.43 | $23.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $10.13 | ★ $22.29 |
| AVG Volume (30 Days) | ★ 1.9M | 727.6K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $888,700,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.58 | N/A |
| P/E Ratio | $18.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.73 | $1.92 |
| 52 Week High | $10.80 | $23.63 |
| Indicator | JBI | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 35.76 | 65.06 |
| Support Level | $5.97 | $21.24 |
| Resistance Level | $6.28 | $23.63 |
| Average True Range (ATR) | 0.24 | 1.98 |
| MACD | 0.14 | 0.10 |
| Stochastic Oscillator | 97.14 | 88.71 |
Janus International Group Inc is a manufacturer and supplier of turnkey solutions for self-storage, commercial, and industrial building Solutions. The company provides products that include roll-up and swing doors, hallway systems, relocatable storage MASS (Moveable Additional Storage Structures) units, and technologies for automating facility and door operation. It is operated through two geographic regions; Janus North America and Janus International. The Janus International segment is comprised of a subsidiary whose production and sales are largely in Europe and Australia. The Janus North America segment is comprised of all the other entities.
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.